Nutex Health reports Q2 prelim revenue $244M (+221% YoY); announces $25M buyback, delays 10-Q

Nutex Health Inc.

2025-Q2 EPS reported $0.55 revenue$455,774,000

Q2 2025 total revenue $244.0M, up 220.7% from $76.1M in Q2 2024; gross profit $124.9M (51.2% margin) vs $22.6M (29.7%).
Hospital visits 45,573 (+10.6% YoY); mature hospital visits up 0.6%.
Delays 10-Q filing due to non-cash accounting adjustments for stock-based compensation on under-construction hospitals; expects to file within 5-day grace period.
Board authorizes stock repurchase program of up to $25.0M over six months, to commence after 10-Q filing, to offset dilution from stock compensation.
Cancels previously scheduled August 15 conference call; will reschedule.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.